Our research team has created a Bluetooth enabled resistance exercise band (BandPass) and a corresponding workout 'app' to help older adults' strength train at home. The purpose of this project is to test the likelihood that BandPass can be used by older adults, to test whether older adults will keep using the device to exercise during the study, and to test if older adults have improved strength at the end of the study.

The purpose of this study is to determine whether inactive adults are able to walk at a moderate pace (100 steps per minute) for 10 minutes when walking on a treadmill, a sidewalk, and a nature trail, and to learn about adults' feelings and mood when walking at a moderate pace. The purpose of this study is to inform future interventions focused on helping inactive adults increase their physical activity participation in fun and enjoyable ways.

The purpose of the study is to find out is AUTX-007 an investigational drug, can help treat or cure cancer.

Testing Radiation Therapy with or without Cisplatin for Head and Neck Cancer

In this study, we're interested in understanding couples' experiences with using ChatGPT and each other for emotional support. We are recruiting couples to take part in a paid virtual study! This study includes 21 days of short online surveys sent via email, and you can earn up to $34 each for your participation.

The purpose of this study is to determine if an investigational medication taken by mouth, called zasocitinib, is safe and works better than deucravacitinib for patients who have moderate to severe plaque psoriasis.

In this study, we want to see if a new drug called LBS-007 can help treat or cure leukemia. We want to find out if it is safe and if it works well for people with this disease.

To evaluate the effect of a new combination of medications on body weight and body fat mass in people with type 2 diabetes and overweight/obesity.

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose.

Are you living with chronic limb-threatening ischemia? You may be dealing with ongoing pain, hard-to-heal wounds, or tough choices about surgeries and treatments to save your leg or foot. We want to hear your story. What has it been like trying to get the care you need? Have you ever felt confused about your treatment options or wished for more support along the way? By sharing your experience, you can help us understand how to improve care for others facing the same condition. Maybe it's helping doctors explain things more clearly, finding better ways to manage pain, or offering support for people worried about losing their independence. We'll talk with you twice-once now and again in six months-to learn about your full journey, the highs and lows, and what really helped. Your voice can lead to real changes that make care better and less stressful for people in the future.